BioCentury
ARTICLE | Clinical News

NexMed enters Phase II with Alprox-TD

February 24, 2000 8:00 AM UTC

NEXM began a 300-patient U.S. Phase II trial of Alprox-TD cream in patients with mild to moderate erectile dysfunction. Alprox-TD is a topical formulation of alprostadil using NEXM's NexACT transderma...